On Jan. 25, 2021, Medigen Vaccine Biologics and Dynavax Technologies announced that the first participant had been dosed in the Phase 2 clinical trial evaluating MVCﾒs COVID-19 vaccine candidate, MVC-COV1901. MVC-COV1901 was a subunit vaccine with recombinant S-2P antigen adjuvanted with CpG 1018 supplied by Dynavax.

MVCﾒs Phase 2 clinical trial was a randomized, double-blinded, multi-center clinical trial, and was expected to enroll 3,700 healthy subjects, 20 years of age and above. The trial evaluated MVC-COV1901 safety and endurance of immunogenicity.